Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RANI

RANI - Rani Therapeutics Holdings, Inc. Stock Price, Fair Value and News

$1.35-0.03 (-2.17%)
Market Closed

Price Targets

Target 1Y

$1.11

Target 3M

$1.25

Target 6M

$1.18

RANI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RANI Price Action

Last 30 days

-2.2%

Last 90 days

-6.9%

Trailing 12 Months

-3.6%

RANI RSI Chart

RANI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RANI Valuation

Market Cap

52.5M

Price/Earnings (Trailing)

-1.67

Price/Sales (Trailing)

65.2

EV/EBITDA

-1.31

Price/Free Cashflow

-1.89

RANI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.11

Target 3M

$1.25

Target 6M

$1.18

RANI Fundamentals

RANI Revenue

Revenue (TTM)

804.5K

Rev. Growth (Yr)

-83.57%

Rev. Growth (Qtr)

-56.96%

RANI Earnings

Earnings (TTM)

-31.4M

Earnings Growth (Yr)

20.21%

Earnings Growth (Qtr)

51.78%

RANI Profitability

EBT Margin

-5900.30%

Return on Equity

262.21%

Return on Assets

-309.65%

Free Cashflow Yield

-52.96%

RANI Investor Care

Shares Dilution (1Y)

34.75%

Diluted EPS (TTM)

-0.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.4M1.2M804.5K0
20243.0M2.5M2.1M1.8M
20232.1M3.0M3.4M3.3M
20222.3M2.0M1.6M1.2M
20211.0M1.6M2.2M2.7M
2020000462.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Rani Therapeutics Holdings, Inc.

RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
 CEO
 WEBSITEranitherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES163

Rani Therapeutics Holdings, Inc. Frequently Asked Questions

RANI is the stock ticker symbol of Rani Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Rani Therapeutics Holdings, Inc. is 52.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RANI's fair value in chart for subscribers.

The fair value guage provides a quick view whether RANI is over valued or under valued. Whether Rani Therapeutics Holdings, Inc. is cheap or expensive depends on the assumptions which impact Rani Therapeutics Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RANI.

As of Wed Jan 28 2026, RANI's PE ratio (Price to Earnings) is -1.67 and Price to Sales (PS) ratio is 65.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RANI PE ratio will change depending on the future growth rate expectations of investors.